ADPKD

24 registered clinical trials studyying ADPKD — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Somatosensory Phenotyping of ADPKD NCT06970028	Universitaire Ziekenhuizen KU Leuven	—
Recruiting	HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life NCT05373264	University Medical Center Groningen	Phase 3
Unknown	Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester? NCT06100133	Universitair Ziekenhuis Brussel	Phase 2
Completed	Genetic Testing in Autosomal Dominant Polycystic Kidney Disease NCT06085807	University of California, San Francisco	—
Completed	A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease NCT05521191	Regulus Therapeutics Inc.	Phase 1
Terminated	Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease NCT04064346	Palladio Biosciences	Phase 3
Recruiting	Kidney Sodium Functional Imaging NCT05014178	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	—
Recruiting	Analysis of Patients With Autosomal Dominant Polycystic Kidney NCT06759142	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Completed	Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD) NCT04680780	University of Cologne	N/A
Unknown	Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt NCT04310319	Esther Meijer	N/A
Terminated	Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Di NCT04152837	Palladio Biosciences	Phase 3
Completed	Short Term Induction of Ketosis in PKD NCT04472624	University of Cologne	N/A
Recruiting	Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study NCT04338048	Children's Hospital of Philadelphia	—
Terminated	A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON NCT03918447	Biogen	Phase 3
Unknown	Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease NCT03764605	Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari	Phase 3
Completed	ADPKD Alterations in Hepatic Transporter Function NCT03717883	University of North Carolina, Chapel Hill	—
Completed	Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD NCT03203642	Kadmon, a Sanofi Company	Phase 2
Active Not Recruiting	Statin Therapy in Patients With Early Stage ADPKD NCT03273413	University of Colorado, Denver	Phase 4
Completed	Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Di NCT02776241	Rigshospitalet, Denmark	N/A
Completed	Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping NCT02161068	The Rogosin Institute	—
Completed	Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPK NCT01853553	University of Colorado, Denver	Phase 3
Completed	The Vienna RAP Pilot Study NCT01632605	Medical University of Vienna	N/A
Recruiting	Genetics in the Progression of Nephropathies NCT06416761	Ospedale San Raffaele	—
Completed	Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic NCT00345137	Regional Hospital Holstebro	Phase 1